Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 5 | Lipids in Health and Disease

Fig. 5

From: Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation

Fig. 5

EMPA promotes autophagosome formation to inhibit obesity-related myocardial inflammation, fibrosis, and hypertrophy. (A) LC3 II/LC3 I levels. (B) Alterations in myocardial fibrosis-related gene expression (Col1a1) and the level of an inflammatory cytokine (Tnf). (C) Impact on the area of H9c2 cells was measured. (D) Oil Red O-positive area in H9c2 cells. N = 3 biological replicates, and each replicate included > 60 cells. *P < 0.05 vs. NC; #P < 0.05 vs. PA; ∆P < 0.05 vs. PA-E

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X